Previous Close | 20.62 |
1-Year Change | 436.98% |
6-Months Change | 116.14% |
3-Months Change | -1.29% |
Moving Avg (50d) | 19.211 |
Moving Avg (200d) | 14.362 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 14.4B |
Beta (3-Years) | 0.31 |
Revenue Growth (ttm) | -100% |
Net Profit Margin (ttm) | % |
Return On Assets (ttm) | -273.53% |
EPS (ttm) | -1.52 |
PE Ratio (ttm) | -13.57 |
Dividend Yield | % |
Asset Description: | Summit Therapeutics Inc. |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2025-01-21 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
20.208 | 19.589 | 19.177 | 18.558 | 17.527 | 16.496 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.